Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,373 total articles
Alterity Therapeutics announced positive regulatory feedback from the FDA following their second Type C Meeting concerning the chemistry, manufacturing, and control aspects of their planned Phase 3 trial for ATH434 in Multiple System Atrophy (MSA). This progress marks a crucial step toward initiating the pivotal trial, with concurrent manufacturing…
Sagimet Biosciences has priced an underwritten offering of 29.17 million Series A common stock shares at $6.00 each, aiming to raise approximately $175 million. The proceeds will fund late-stage clinical trials including a Phase 3 study for denifanstat in moderate to severe acne, advance pipeline candidates through Phase 2 results, and support gene…
Allot Ltd., a global provider of Security-as-a-Service and network intelligence solutions, announced it will release its first quarter 2026 financial results and hold a conference call on May 12, 2026. The company provides cybersecurity and network analytics solutions to service providers and enterprises worldwide.
HBT Financial, Inc. announced first quarter 2026 results with net income of $11.2 million ($0.34 per diluted share) and adjusted net income of $22.6 million ($0.68 per diluted share). The company completed its merger with CNB Bank Shares, Inc. on March 1, 2026, successfully integrating systems. Asset quality remained strong with low nonperforming a…
Youxin Technology Ltd announced it will acquire an 18% equity stake in YATOP Group Limited, a leading TikTok marketing and branding agency, for approximately $10.8 million via share exchange. This strategic investment aims to enhance Youxin's SaaS and PaaS digital commerce ecosystem by integrating YATOP's strong global influencer marketing and e-co…
Purple Biotech announced new preclinical data validating the efficacy of IM1240, its lead CAPTN-3 tri-specific antibody. Generated by Dr. Amir Horowitz's team at Mount Sinai, the data shows IM1240's NKG2A arm significantly enhances anti-tumor activity across multiple resistant patient-derived tumor samples, including PD-1 resistant cancers. The ant…
Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for approximately $739 million in cash, adding over 120 assets including seven marketed products and significantly expanding its royalty portfolio across multiple therapeutic areas. The acquisition is expected to be immediately accretive to adjusted EPS and has prompted Li…
Aurora Mobile's sub-brand MoonFox Data showcased its sophisticated multi-dimensional alternative data platform at the Neudata Hong Kong Summit, demonstrating how its online, offline, transactional, and sentiment data enable investors to forecast earnings and generate alpha in Chinese markets. MoonFox highlighted its extensive coverage of over 600 l…
Seer, Inc.'s Board of Directors unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group offering $2.35 per share plus contingent value rights. The Board stated the offer significantly undervalues Seer considering its strong growth potential, proprietary proteomics platform, increasing adoption, and large market opp…
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. starting in the second half of 2026, following positive Phase 3 results reported in China. The company is also advancing its FASN inhibitor pipeline with an ongoing Phase 1 trial of TVB-3567 and is prioritizing dermatology…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, has announced its participation in various upcoming scientific and investor conferences in May 2026. The company will present clinical trial results, particularly for its investigational product AXPAXLI (OTX-TKI), currently in Phase 3 trials for wet age-related m…
Intellia Therapeutics has started a rolling submission of a biologics license application to the FDA seeking approval for lonvoguran ziclumeran (lonvo-z), an innovative one-time in vivo CRISPR gene-editing treatment for hereditary angioedema (HAE). Positive topline Phase 3 HAELO trial data indicate that lonvo-z met primary and secondary endpoints, …
Harrow, a Nasdaq-listed ophthalmic disease management company, will release its financial results for Q1 2026 after market close on May 11, followed by a conference call on May 12 to discuss the results and provide a business update.
Cardiff Oncology announced it will host a key opinion leader webinar on April 30, 2026, to discuss data from an investigator-initiated trial showing onvansertib's promising single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The event features Dr. Mrinal Patnaik from Mayo Clinic and aims to highlight onvansertib's potential as…
U.S. Energy Corp. (NASDAQ: USEG) announced a five-year helium sales agreement with an investment-grade global industrial gas company for helium produced at its Big Sky Carbon Hub in Montana. The contract guarantees purchase of 100% of Phase 1 helium production at a fixed plant-gate price of $285 per thousand cubic feet with annual inflation adjustm…
GXO Logistics, the largest pure-play contract logistics provider, announced its partnership with the Arrow McLaren IndyCar Team as an Official Partner for the 110th Running of the Indianapolis 500. GXO branding will be prominently featured on the No. 31 car driven by Ryan Hunter-Reay. This partnership aligns GXO's values of teamwork, precision, and…
Intellia Therapeutics reported positive topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene editing therapy targeting hereditary angioedema (HAE). The trial met its primary and all key secondary endpoints, showing an 87% reduction in attacks over six months versus placebo, with favo…
Altimmune, Inc. has completed an oversubscribed public offering raising $225 million in gross proceeds to fund its upcoming Phase 3 clinical trial of pemvidutide, a novel therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and other serious liver diseases. The financing provides cash runway through the anticipated 52-week data…
Martin Marietta Materials, Inc., a leading supplier of aggregates and building materials, appointed Chris Samborski as Executive Vice President and Chief Operating Officer effective May 1, 2026. Samborski brings extensive leadership experience from his previous roles within Martin Marietta and other major corporations such as Caterpillar and Johnso…
Verizon Communications Inc. reported solid financial and operating results for the first quarter of 2026, showcasing accelerating momentum in its strategic transformation efforts. The company achieved its highest quarterly adjusted EBITDA in history, positive postpaid phone net additions for the first time in over a decade, and raised its 2026 adju…
Oruka Therapeutics announced positive interim data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis patients. The treatment achieved a 63.5% complete skin clearance rate (PASI 100) at 16 weeks with a safety profile similar to placebo and existing IL-23p19 inhibitors. Updated pharmacokinetic data support potentia…
Astec Industries, a manufacturer of specialized equipment for asphalt road building, aggregate processing, and concrete production, announced a quarterly dividend of $0.13 per share payable on May 29, 2026, to shareholders of record on May 13, 2026. The company operates in two main segments: Infrastructure Solutions and Materials Solutions, and als…
Sionna Therapeutics has completed enrollment in its PreciSION CF Phase 2a proof-of-concept trial, which evaluates its first-in-class NBD1 stabilizer, SION-719, added to the current cystic fibrosis standard of care Trikafta. Data from the trial is expected in summer 2026. This marks the first clinical study targeting the nucleotide binding domain 1 …
Fulcrum Therapeutics announced positive clinical data from its Phase 1b PIONEER trial of pociredir for sickle cell disease, showing significant fetal hemoglobin induction and improvements in markers of hemolysis, anemia, and potential reduction in vaso-occlusive crises. The company plans to initiate a registration-enabling trial in the second half …
Lakeland Financial Corporation announced record first quarter 2026 net income of $26.5 million, a 32% increase from the prior year quarter, driven by 5% loan growth, strong net interest margin expansion, and 18% higher noninterest income. The bank experienced healthy organic loan growth, improved asset quality, and increased shareholder returns via…
